MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fneur.2018.00150

Медицинская библиотека · Frontiers in neurology · 2018

Myasthenia Gravis Induced by Ipilimumab in a Patient With Metastatic Melanoma.

Montes Vera, Sousa Sandra, Pita Fernando, Guerreiro Rui, Carmona Cátia

Клинический случайСтатьяПеревод пока не подготовлен

Аннотация

In daily clinical practice, there is a growing number of patients receiving new biological agents used in the treatment of malignancies. Ipilimumab is a fully humanized monoclonal antibody approved for patients with melanoma. It acts as an immune checkpoint inhibitor, binding and blocking cytotoxic T-lymphocyte antigen-4 in order to increase the antitumor immune response. There are several reports of autoimmune responses after its use. A 74-year-old man developed a mild rash and pruritus a few hours after the second infusion of ipilimumab and 24 h after the third dose of ipilimumab, he presented with shortness of breath, proximal limb muscle weakness, and diplopia. Repetitive nerve stimulation was consistent with a postsynaptic neuromuscular junction disorder. He began therapy with corticosteroids and pyridostigmine and ipilimumab was discontinued. Following ipilimumab suspension, the patient started to improve gradually. Here, we describe a rare case of myasthenia gravis presumably related with ipilimumab's therapy. A better knowledge of these agents is necessary, in order to identify characteristics or biomarkers that may be associated with the development of potentially serious autoimmune responses.

Для цитирования: Montes Vera, Sousa Sandra, Pita Fernando, Guerreiro Rui, Carmona Cátia. Myasthenia Gravis Induced by Ipilimumab in a Patient With Metastatic Melanoma.. Frontiers in neurology. 2018. DOI: 10.3389/fneur.2018.00150.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.